ADC Therapeutics Secures $86.6 Million PIPE to Extend Cash Runway into 2029

Key numbers

Deal value	$87M
Share of market cap	36.5%

Key highlights

• $86.6 million total gross proceeds raised through shares and pre-funded warrants
• New participation from Bain Capital Life Sciences alongside existing investor Redmile
• Operational cash runway now expected to extend through the end of 2028 into 2029
• Parallel restructuring includes reducing senior secured loan principal to $50 million
• Capital specifically earmarked for ZYNLONTA Phase 3 trials in DLBCL and MZL

What Is the Capital Raise?

ADC Therapeutics has structured a $86.6 million private investment in public equity transaction involving both common shares and pre-funded warrants. The deal includes the sale of 12,911,347 common shares at a fixed price of $1.42 per share and pre-funded warrants for an additional 48,088,653 shares. These warrants are priced at $1.324 each, representing the share price minus a nominal exercise cost. The offering, which involves high-profile backers like Bain Capital Life Sciences and TCGX, is scheduled to close on October 22, 2026. The company has committed to filing a resale registration statement within 30 business days of the closing date.

Down 8.6% since our story on 13 Oct: $1.86 when we broke it → $1.70 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$1.11
15 Sep	$1.09
16 Sep	$1.05
17 Sep	$1.06
18 Sep	$1.05
21 Sep	$1.12
22 Sep	$1.23
23 Sep	$1.31
24 Sep	$1.29
25 Sep	$1.27
28 Sep	$1.26
29 Sep	$1.23
30 Sep	$1.22
1 Oct	$1.08
2 Oct	$1.13
5 Oct	$1.23
6 Oct	$1.27
7 Oct	$1.42
8 Oct	$1.59
9 Oct	$1.73
12 Oct	$1.86
13 Oct	$1.70

Strategic Rationale

This financing serves as the cornerstone of a comprehensive strategic financial restructuring designed to enhance balance sheet flexibility. Concurrent with the equity raise, the company amended its Purchase and Sale Agreement with HealthCare Royalty to eliminate specific change-of-control payment obligations. Furthermore, ADC Therapeutics refinanced its senior secured debt, lowering the principal to $50 million with a maturity date in August 2029. These coordinated moves effectively remove minimum liquidity requirements and extend the company's cash runway by several years, providing the necessary stability to reach major clinical milestones for its antibody-drug conjugate portfolio without immediate funding pressure.

Use of Proceeds

• Financing Phase 3 clinical studies for ZYNLONTA in combination with glofitamab for DLBCL
• Advancing the monotherapy Phase 3 trial of ZYNLONTA for marginal zone lymphoma
• Supporting general corporate purposes and providing essential working capital through 2029
• Investing in the continued commercialization and expansion of the ZYNLONTA pipeline
• Strengthening the corporate balance sheet following the recent debt principal reduction

Financial Context

The capital raise arrives as ADC Therapeutics reports significant commercial momentum and positive revenue trajectories. Management recently issued preliminary guidance for the third quarter of 2026, forecasting ZYNLONTA net product revenue of approximately $21.0 million. This growth follows a year where annual revenue reached $81.4 million. The company's stock has reacted sharply to the restructuring news, gaining over 67% in value over the last month. With the cash runway now secured into 2029, the firm is positioned to present critical data abstracts at the upcoming 68th American Society of Hematology Annual Meeting in December.

Management commentary

“These efforts extend our expected cash runway and increase strategic optionality, as we approach much anticipated LOTIS-7 and MZL data abstracts in early November with presentations in December at the 68th American Society of Hematology Annual Meeting.”

ADC Therapeutics SA · financial snapshot

Share price	$1.86
Market cap	$237M
Revenue (annual)	$81M
1-month price change	+67.57%
Sector	HealthcareDrug Manufacturers - Specialty & Generic

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.